Literature DB >> 7679323

Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group.

R D Gelber1, A Goldhirsch, B F Cole.   

Abstract

The effectiveness of cancer treatments is often expressed in terms of disease-free survival or overall survival relative risk reduction or odds ratios, and the quality of life effects are often assessed separately from survival. Such end points and summary measures may be inadequate, however, for comparing two treatments in terms of their palliative effects because there is a trade-off between treatment toxicity and increased disease-free interval. Furthermore, this trade-off may depend on individual patient preferences and prognostic situations. The goal of this paper is to describe a method for evaluating the effectiveness of cancer treatments in terms of palliation by simultaneously considering both quality and quantity of time following treatment so that therapeutic choice may be determined according to patient preferences on quality of life and prognostic situation. The method we present is an extension of the Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) method for comparing treatment effectiveness in clinical trials of adjuvant therapies. We illustrate an application using data from the International Breast Cancer Study Group Trial V which compares two chemotherapy schedules with different toxicities.

Entities:  

Mesh:

Year:  1993        PMID: 7679323     DOI: 10.1016/0305-7372(93)90060-5

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  14 in total

Review 1.  Brain tumor clinical trials: pitfalls and promise for the future.

Authors:  M R Gilbert
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

2.  Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer.

Authors:  Emilie Le Rhun; Jennifer Wallet; Audrey Mailliez; Marie Cecile Le Deley; Isabelle Rodrigues; Thomas Boulanger; Veronique Lorgis; Jerome Barrière; Yves Marie Robin; Michael Weller; Jacques Bonneterre
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

3.  Quality of life bibliography and indexes: 1993 update.

Authors:  R A Berzon; G P Simeon; R L Simpson; M A Donnelly; H H Tilson
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

4.  Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.

Authors:  Raymond W Jang; Aurélie Le Maître; Keyue Ding; Tim Winton; Andrea Bezjak; Lesley Seymour; Frances A Shepherd; Natasha B Leighl
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 5.  The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.

Authors:  Andrea Messori; Dario Maratea; Chiara Nozzoli; Alberto Bosi
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

6.  Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

Authors:  Meredith M Regan; Opeyemi A Jegede; Charlene M Mantia; Thomas Powles; Lillian Werner; Robert J Motzer; Nizar M Tannir; Chung-Han Lee; Yoshihiko Tomita; Martin H Voss; Elizabeth R Plimack; Toni K Choueiri; Brian I Rini; Hans J Hammers; Bernard Escudier; Laurence Albiges; Stephen Huo; Viviana Del Tejo; Brian Stwalley; Michael B Atkins; David F McDermott
Journal:  Clin Cancer Res       Date:  2021-11-10       Impact factor: 13.801

7.  Outcomes research in cancer clinical trial cooperative groups: the RTOG model.

Authors:  D W Bruner; B Movsas; A Konski; M Roach; M Bondy; C Scarintino; C Scott; W Curran
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

Review 8.  A framework for organizing and selecting quantitative approaches for benefit-harm assessment.

Authors:  Milo A Puhan; Sonal Singh; Carlos O Weiss; Ravi Varadhan; Cynthia M Boyd
Journal:  BMC Med Res Methodol       Date:  2012-11-19       Impact factor: 4.615

9.  Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.

Authors:  Marcos Aurélio Fonseca Magalhães Filho; Pedro Nazareth Aguiar; Milena Brachmans Mascarenhas Neves; Gilberto de Lima Lopes; Auro Del Giglio
Journal:  Einstein (Sao Paulo)       Date:  2022-05-06

10.  Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer.

Authors:  N B Leighl; F A Shepherd; D Zawisza; R L Burkes; R Feld; J Waldron; A Sun; D Payne; A Bezjak; M H N Tattersall
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.